Breast最新文献

{"title":"Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review.","authors":"Javier Muñoz, Sabrina Nucera, Nuria Rubira Garcia, Isaac Cebrecos, Gabriela Oses, Sergi Ganau, Esther Sanfeliu, Pedro Jares, Mercedes Marín-Aguilera, Patricia Galván, Fara Brasó-Maristany, Olga Martínez-Sáez, Enric Cascos, Carme Font, Francesco Schettini","doi":"10.1016/j.breast.2025.104465","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104465","url":null,"abstract":"<p><p>We present the first documented oncologic case of a type I Kounis syndrome (KS) following paclitaxel administration, in a very young patient with HER2-positive(+) early-stage breast cancer (BC). KS is a relatively rare acute coronary syndrome triggered by anaphylactic or hypersensitivity reactions, of which there is limited awareness among healthcare providers. It is subdivided in four subtypes depending on cardiac artery medical history. While no established management guidelines exist, its treatment requires addressing severe infusion reactions while ensuring proper myocardial perfusion. We hereby illustrate its successful acute management and report on how tumor genomics through the novel HER2DX assay helped re-defining the entire neo/adjuvant oncologic strategy. HER2DX integrates tumor size and nodal involvement with 27 genes' expression data tracking four biological BC-related and immunologic signatures so to estimate a prognostic and a predictive score. This report demonstrates how clinical and genomic data can be effectively integrated to optimize therapeutic decisions in HER2+ BC, offering a model for personalized care also in atypical and complex cases.</p>","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"104465"},"PeriodicalIF":5.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study","authors":"Xuenan Peng ,&nbsp;Bo Lan ,&nbsp;Jiayu Wang ,&nbsp;Qiao Li ,&nbsp;Jiani Wang ,&nbsp;Ying Fan ,&nbsp;Yang Luo ,&nbsp;Shanshan Chen ,&nbsp;Hongnan Mo ,&nbsp;Lixi Li ,&nbsp;Xiaoying Sun ,&nbsp;Jintao Zhang ,&nbsp;Ruigang Cai ,&nbsp;Pin Zhang ,&nbsp;Binghe Xu ,&nbsp;Fei Ma","doi":"10.1016/j.breast.2025.104470","DOIUrl":"10.1016/j.breast.2025.104470","url":null,"abstract":"<div><h3>Background</h3><div>A growing number of antibody‒drug conjugates (ADCs) have been approved for breast cancer treatment. However, the proper sequential strategies of ADCs remain uncertain. Our study aimed to explore the ideal ADC sequential treatment strategies in human epidermal growth factor receptor 2 (HER2)-expressing metastatic breast cancer (MBC).</div></div><div><h3>Methods</h3><div>Our multi-centre retrospective study enrolled MBC patients who received at least 2 lines of different types of ADCs between Jan 1, 2018, and Jul 1, 2024. The efficacy of both ADC1 and ADC2 was evaluated.</div></div><div><h3>Results</h3><div>A total of 111 patients (83 HER2-positive and 28 HER2-low) were included. In HER2-positive populations, Patients who received ADC2 with a different payload from ADC1 exhibited significantly longer progression-free survival 2 (PFS2) (6.8 vs. 2.7 months, <em>p</em> &lt; 0.001) and overall PFS (progression-free Interval 1 (PFI1) + PFS2) (15.0 vs. 8.5 months, <em>p</em> = 0.043) compared to those treated with ADC2 containing a similar payload with ADC1. Patients received ADC2 immediately after ADC1 progression showed longer PFS2 ADC2 delayed sequential patients (median PFS2: 6.0 vs. 3.0 months, <em>p</em> = 0.004). In HER2-low patients, the efficacy of ADC2 tended to be lower than ADC1 (median PFI1 vs. PFS2: 3.1 vs. 2.4 months, <em>p</em> = 0.078). No significant differences of efficacy were observed, no matter what ADC sequential treatment strategy used.</div></div><div><h3>Conclusions</h3><div>Sequential treatment with ADCs showed clinical benefit especially for HER2-positive patients treated with ADC2 which have different types of payloads from ADC1. In HER2-low patients, the benefit of ADC sequential therapy seemed to be limited.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104470"},"PeriodicalIF":5.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-reported cognitive function in older breast cancer survivors after chemotherapy treatment","authors":"Rachel Kim ,&nbsp;Julia Peña ,&nbsp;Kai-Ping Liao ,&nbsp;Susan K. Peterson ,&nbsp;Liang Li ,&nbsp;Daria Zorzi ,&nbsp;Holly M. Holmes ,&nbsp;Mariana Chavez-MacGregor ,&nbsp;Sharon H. Giordano","doi":"10.1016/j.breast.2025.104468","DOIUrl":"10.1016/j.breast.2025.104468","url":null,"abstract":"<div><h3>Purpose</h3><div>This study evaluated self-reported cognitive function in older breast cancer survivors and its association with prior chemotherapy.</div></div><div><h3>Materials and methods</h3><div>Breast cancer survivors aged 65-years and older, diagnosed 2012–2013, with local and regional stage disease, were identified through the linked Texas Cancer Registry-Medicare dataset. Survivors completed the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-CogV3) instrument and provided demographic and clinical data. A PCI--sub-score of less than 54 was used to identify cognitive impairment. Linear regression models were used to examine the FACT-CogV3 primary score, and logistic regression models evaluated the PCI--sub-score.</div></div><div><h3>Results</h3><div>Of 4448 eligible survivors, 1594 (35.8 %) completed the FACT-Cog and 1065 completed all questions. The median time from diagnosis to survey completion was 68 months The median age at survey completion was 76 years. 26 % of patients had received adjuvant chemotherapy. In adjusted models, decreased FACT-Cog primary scores were associated with age 80-years and older (p&lt;0.01 vs. age 65–69) and with depression (p &lt; 0.01), and increased scores were associated with an education of 4-year college and above (p = 0.01).</div><div>For the PCI-subscale, 243 patients (27.9 %) reported PCI-score &lt;54. In the adjusted models, patients who were older than 80-years were more likely to report perceived cognitive impairment (OR 3.03, vs age 65–69), as well as those with depression (OR 6.19, p &lt; 0.01). Prior chemotherapy was not a significant predictor of PCI (OR 1.49, p = 0.06).</div></div><div><h3>Conclusion</h3><div>Adjuvant chemotherapy was not significantly associated with self-reported cognitive impairment in older breast cancer survivors 5–6 years after diagnosis.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104468"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC","authors":"Elena Laakmann ,&nbsp;Marcus Schmidt ,&nbsp;Kristina Lübbe ,&nbsp;Elisa Agostinetto ,&nbsp;Mette van Ramshorst ,&nbsp;Thomas Decker ,&nbsp;Wolfram Malter ,&nbsp;Francesco Schettini ,&nbsp;Mario Fontes Sousa ,&nbsp;Carsten Denkert ,&nbsp;Tanja Neunhöffer ,&nbsp;Leonor Matos ,&nbsp;Sabine Linn ,&nbsp;Marc Thill ,&nbsp;Rudolf Weide ,&nbsp;Amanda Fitzpatrick ,&nbsp;Marta Vaz Batista ,&nbsp;Christoph Mundhenke ,&nbsp;Tjoung-Won Park-Simon ,&nbsp;Fanny Le Du ,&nbsp;Volkmar Müller","doi":"10.1016/j.breast.2025.104433","DOIUrl":"10.1016/j.breast.2025.104433","url":null,"abstract":"<div><h3>Background</h3><div>Leptomeningeal metastases (LM) in patients with breast cancer (BC) are associated with a dismal prognosis. We explored clinical characteristics and prognostic factors in patients with BC and LM in the German Brain Metastases in Breast Cancer Registry.</div></div><div><h3>Methods</h3><div>All patients with histologically confirmed BC and diagnosis of LM (defined as the presence of tumor cells in the cerebrospinal fluid, or presence of typical clinical symptoms in combination with typical magnetic resonance imaging findings) were included.</div></div><div><h3>Results</h3><div>A total of 3857 patients were included in the analysis (n = 859 (22.3 %) with LM). Among patients with LM a median progression-free survival was 4.2 months (95 % CI 3.6–4.8), and median overall survival was 5.7 months (95 % CI 4.9–6.7). In the multivariate analysis older age ( ≥ 60 vs. &lt;60 years, Hazard ratio (HR): 1.65, 95 %CI: 1.25–2.18), worse performance status (ECOG 2–4 vs. 0–1 HR: 2.15, 95 %CI: 1.63–2.82), hormone receptor positive/HER2-negative (HR+/HER2-) or triple-negative subtype (HR: 1.54 95CI%: 1.07–2.23 and HR: 1.87, 95 %CI: 1.25–2.81), and higher number of BM (2–3 vs. 1, HR: 1.49, 95 %CI: 1.05–2.11 4) were significantly associated with a higher risk of death. Stereotactic radiotherapy (HR 0.49 95 %CI 0.30–0.79) and whole brain irradiation (HR: 0.58, 95 %CI: 0.42–0.80), endocrine therapy in patients with HR + BC (HR: 0.31, 95 %CI: 0.21–0.45) as well as HER2-targeted therapy for patients with HER2+ BC (HR 0.41, 95 %CI: 0.25–0.68) were associated with a significantly longer survival.</div></div><div><h3>Conclusions</h3><div>Clinicopathological factors associated with survival can help clinicians identify patients who are candidates for treatment (de)escalation in clinical trials.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104433"},"PeriodicalIF":5.7,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping breast cancer therapy with circulating tumor cells: The expert perspective","authors":"Lorenzo Gerratana ,&nbsp;Caterina Gianni ,&nbsp;Eleonora Nicolò ,&nbsp;Letizia Pontolillo ,&nbsp;Francois-Clement Bidard ,&nbsp;Carolina Reduzzi ,&nbsp;Massimo Cristofanilli","doi":"10.1016/j.breast.2025.104463","DOIUrl":"10.1016/j.breast.2025.104463","url":null,"abstract":"<div><div>Circulating tumor cells (CTCs) have emerged as a key prognostic biomarker for breast cancer, with their role becoming more pronounced in metastatic cases. In metastatic breast cancer, having five or more CTCs per 7.5 mL of blood is linked to poorer survival and more aggressive disease, marking it as stage IV_aggressive. Conversely, fewer than five CTCs per 7.5 mL of blood indicates a less aggressive, stage IV_indolent disease. Additionally, molecular CTCs characterization provides a real-time snapshot of tumor biology, capturing its temporal and spatial variability and providing insights into tumor behavior.</div><div>Beyond their role in predicting outcomes, CTCs can help guide treatment intensity as shown in clinical trials like the STIC trial, offering a new way to tailor therapy alongside other liquid biopsy biomarkers such as circulating tumor DNA.</div><div>The aim of our review is to focus on both enumeration and phenotyping of CTCs and examine how CTC-guided strategies can improve treatment tailoring and patient outcomes. We also explore the potential for integrating CTCs with other biomarkers, such as circulating tumor DNA, and discuss how innovative biomarker-driven clinical trial designs could further advance personalized treatment strategies.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104463"},"PeriodicalIF":5.7,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143777548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computational pathology for breast cancer: Where do we stand for prognostic applications?","authors":"Grégoire Gessain ,&nbsp;Magali Lacroix-Triki","doi":"10.1016/j.breast.2025.104464","DOIUrl":"10.1016/j.breast.2025.104464","url":null,"abstract":"<div><div>The very early days of artificial intelligence (AI) in healthcare are behind us. AI is now spreading in the healthcare sector and is gradually being implemented in routine clinical practice. Driven by the increasing digitization of microscope slides, computational pathology (CPath) is further strengthening the role of AI in the field of oncology. CPath is transforming fundamental research as well as routine clinical practice, both for diagnostic and prognostic applications. In breast cancer, CPath holds the potential to address several unmet clinical needs, particularly in the areas of biomarkers and prognostic tools. Indeed, multiple applications are on their way, ranging from predicting clinically meaningful endpoints to offering alternatives to gene-expression testing and detecting molecular alterations directly from digitized whole slide images. However, to fully harness the potential of CPath, several challenges must be overcome. These include improving the availability of multimodal patient data, advancing the digitalization of pathology laboratories, increasing adoption within the medical community, and navigating regulatory hurdles. This review offers an overview of the current landscape of CPath in breast cancer, highlighting the progress made and the hurdles that remain for its widespread clinical adoption in prognostic applications.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104464"},"PeriodicalIF":5.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry","authors":"Tomoe Taji ,&nbsp;Hiraku Kumamaru ,&nbsp;Yuki Kataoka ,&nbsp;Kotaro Iijima ,&nbsp;Hirofumi Suwa ,&nbsp;Hiroshi Ishiguro ,&nbsp;Naruto Taira ,&nbsp;Takanori Ishida ,&nbsp;Shigehira Saji","doi":"10.1016/j.breast.2025.104460","DOIUrl":"10.1016/j.breast.2025.104460","url":null,"abstract":"<div><h3>Background</h3><div>While neoadjuvant chemotherapy (NAC) is recommended for stage II-III triple-negative breast cancer (TNBC), its equivalence to adjuvant chemotherapy (AdjC) has been questioned based on a retrospective study using the National Cancer Database in the United States, which lacked adjustment for important covariates. Given the unlikelihood of new randomized trials being conducted, well-designed, large-scale, retrospective studies are needed.</div></div><div><h3>Patients and methods</h3><div>We retrospectively analyzed operable TNBC patients from the Japanese National Clinical Database- Breast Cancer Registry (2012–2016). Inclusion criteria were clinical stage I-IIIB, estrogen receptor (ER) &lt; 10 %, progesterone receptor (PgR) &lt; 10 %, and HER2-negative. We excluded patients with carcinoma in situ, cT4a/T4c/T4d, cN3, cM1, bilateral breast cancer, male, non-epithelial tumor, no chemotherapy, no surgery and no follow-up. Primary and secondary outcomes of overall survival (OS) and recurrence-free survival (RFS) were compared between NAC and AdjC using Cox proportional Hazard regression among the exact matched cohort based on age, BMI, cT, cN, histology, ER/PgR positivity, chemotherapy regimen, breast operative technique, radiotherapy, and institution size.</div></div><div><h3>Results</h3><div>Among 9,000 AdjC and 5,520 NAC patients, 3,256 matched cases were compared. OS and RFS were significantly worse for patients with NAC (Hazard Ratio 1.45 (95 % confidence interval 1.26–1.68) and 1.33 (1.19–1.49), respectively), particularly in patients &lt;65 years, with stage II-IIIB, and with invasive ductal carcinoma.</div></div><div><h3>Conclusion</h3><div>Patients with NAC had worse prognosis, possibly due to unadjusted confounders. Although the availability of immune checkpoint inhibitors (ICIs) limits the clinical impact, the result could provide supplemental insights for treatment decisions in patients who are not candidates for ICIs.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104460"},"PeriodicalIF":5.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143726141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reevaluating prognostic differences in HR+/HER2- Breast Cancer: The unaccounted impact of CDK4/6 inhibitors.","authors":"Arif Hakan Önder","doi":"10.1016/j.breast.2025.104462","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104462","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"104462"},"PeriodicalIF":5.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards precision therapy in HER2-positive early-stage breast cancer.","authors":"Serena Di Cosimo, Paolo Verderio","doi":"10.1016/j.breast.2025.104461","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104461","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"104461"},"PeriodicalIF":5.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk","authors":"Volkmar Müller ,&nbsp;Manuel Hörner ,&nbsp;Marc Thill ,&nbsp;Maggie Banys-Paluchowski ,&nbsp;Sabine Schmatloch ,&nbsp;Peter A. Fasching ,&nbsp;Nadia Harbeck ,&nbsp;Dagmar Langanke ,&nbsp;Sabrina Uhrig ,&nbsp;Lothar Häberle ,&nbsp;Dorothea Fischer ,&nbsp;Alexander Hein ,&nbsp;Tanja N. Fehm ,&nbsp;Chloë Goossens ,&nbsp;Jürgen Terhaag ,&nbsp;Uwe Heilenkötter ,&nbsp;Peter Dall ,&nbsp;Christian Rudlowski ,&nbsp;Rachel Wuerstlein ,&nbsp;Mustafa Aydogdu ,&nbsp;Andreas D. Hartkopf","doi":"10.1016/j.breast.2025.104458","DOIUrl":"10.1016/j.breast.2025.104458","url":null,"abstract":"<div><h3>Background</h3><div>The optimal adjuvant endocrine treatment in premenopausal patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) early breast cancer (eBC) remains debated, particularly the choice between aromatase inhibitors plus ovarian function suppression (AI + OFS) or tamoxifen (TAM) with or without additional OFS. This study assessed the use of adjuvant endocrine therapies for premenopausal patients with intermediate/high-risk HRpos/HER2neg eBC.</div></div><div><h3>Methods</h3><div>CLEAR-B (AGO-B-059; NCT05870813) was a retrospective study analyzing data, collected from January 2016 to June 2019 and from January 2022 to December 2023 during the certification process of breast centers in Germany. Premenopausal patients with HRpos/HER2neg intermediate/high-risk eBC were eligible. Patient and disease characteristics, in addition to recommended and received adjuvant treatments, were evaluated.</div></div><div><h3>Results</h3><div>The number of registered patients was 3137, of whom 2789 had complete information on endocrine treatments (1717 for 2016–2019 and 1072 for 2022–2023). In 2016–2019, 8.4 % of the patients were recommended to be treated with AI + OFS, whereas in 2022–2023, the proportion of patients with a treatment recommendation for AI + OFS rose to 42.1 %. In 2016–2019, TAM monotherapy was most frequently recommended (80.8 %). Conversely, TAM + OFS was not commonly recommended (9.3 % in 2016–2019 and 16.5 % in 2022–2023). While no clear association between tumor stage and chosen endocrine therapy was found in 2016–2019, most patients with ≥stage IIA were recommended to be treated with AI + OFS in 2022–2023.</div></div><div><h3>Conclusion</h3><div>This analysis shows that treatment recommendation for AI + OFS in premenopausal patients with HRpos/HER2neg eBC increased relevantly in the past years, reflecting latest guideline recommendations.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104458"},"PeriodicalIF":5.7,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}